First-line axitinib plus pembrolizumab supported in treatment of renal cell carcinoma
Click Here to Manage Email Alerts
A presentation at ASCO Annual Meeting supported the use of first-line axitinib and pembrolizumab in the treatment of patients with advanced renal cell carcinoma.
Patients with confirmed stage IV metastatic renal cell carcinoma who had initiated first-line axitinib (Inlyta, Pfizer) and pembrolizumab (Keytruda, Merck) on or after Jan. 1, 2018, to July 31, 2022, from 280 cancer clinics in the U.S. were included in the study.
Yousef Zakharia, MD, clinical associate professor at University of Iowa Carver College of Medicine, and colleagues reported on an extended follow-up of 19.2 months. Analyses included the best overall response to the therapy; real-world PFS and OS at landmark time periods of 3, 6, 9, 12, 18 and 24 months.
At diagnosis, 56.5% of patients had stage IV renal cell carcinoma and 78.2% had clear cell histology. IMDC Risk Score was favorable in 6.8% of patients, intermediate in 34.4% and poor in 22.1%.
At analysis, 192 patients had received only first-line axitinib and pembrolizumab and 148 patients had received one or more subsequent lines of treatment. The most commonly used second-line treatments were vascular endothelial growth factor receptor inhibitors — cabozantinib (Cabometyx, Exelixis), most frequently (84 patients, 77.1%) .
Researchers noted a median real-world PFS of 8.6 months, median real-world OS of 29.4 months, and best ORR of 54.1%. The researchers said the updated analysis of this therapy gives further understanding of the clinical outcomes and treatment patterns of patients in the U.S.
Collapse
Zakharia Y, et al. Abstract e16553. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Read more about
Click Here to Manage Email Alerts